DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
> This Story

Forward Printable StoryPrint Comment




Rad Oncology Homepage

Varian to deliver six technical presentations at ICCR

Shandong Cancer Hospital proton center joins FlashForward Consortium for flash proton therapy research

Varian Medical Systems presents latest innovations in radiotherapy at DEGRO 25

Merit Medical awarded interventional fluid management agreement with Premier

RaySearch to exhibit the latest news for particle therapy at PTCOG 58

Flash irradiation delivered in a IBA ProteusONE proton therapy treatment room

Varian announces acquisitions of Endocare and Alicon

Herlev University Hospital treats first patient in Denmark on Varian Halcyon system

Varian to host FlashForward Consortium meeting at PTCOG58

Varian-equipped New York Proton Therapy Center opens with ribbon cutting event

AngioDynamics receives FDA approval to initiate pilot study for use of NanoKnife to treat prostate cancer

Press releases may be edited for formatting or style
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational device exemption (IDE) application for its NanoKnife® Irreversible Electroporation pilot study for the ablation of prostate cancer tissue in low-risk patients.

The prospective, non-randomized pilot study includes six subjects at up to three clinical sites. The pilot study is intended to inform the design of a pivotal clinical study in the United States to support the approval of a future Premarket Approval Application (PMA).

Story Continues Below Advertisement

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

“On the heels of our first patient enrollment in our Stage III pancreatic cancer IDE, we are excited to receive approval to conduct a separate pilot IDE for the treatment of prostate cancer,” said Brent Boucher, AngioDynamics Senior Vice President and General Manager of Oncology. “This pilot study represents the next step in our comprehensive approach to establish NanoKnife® as a platform technology to treat numerous cancers and conditions.”

Prostate cancer is the second leading cause of cancer death in American men1. Approximately one man out of every nine will be diagnosed with prostate cancer during his lifetime1. Traditional treatment options have focused on standard whole-gland therapies, such as active surveillance, radical prostatectomy, and external beam radiation2. However, over the last decade, focal therapy has been evaluated as an alternative for select patients diagnosed with localized prostate cancer in order to minimize treatment-related toxicity2.

The NanoKnife® System is a unique, minimally invasive technique that has been used to successfully treat focal prostate lesions through irreversible electroporation.

About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. For more information, visit

About the NanoKnife System
The NanoKnife System has received 510(k) clearance from the Food and Drug Administration for the surgical ablation of soft tissue. The NanoKnife System utilizes low energy direct current electrical pulses to permanently open pores in target cell membranes. These permanent pores, or nano-scale defects, in the cell membranes result in cell death. The treated tissue is then removed by the body's natural processes over a matter of weeks, mimicking natural cell death. Unlike other ablation technologies, the NanoKnife System does not achieve tissue ablation using thermal energy.

The NanoKnife System consists of two major components: a Low Energy Direct Current, or LEDC Generator and needle-like electrode probes. Up to six electrode probes can be placed into or around the targeted soft tissue. Once the probes are in place, the user enters the appropriate parameters for voltage, number of pulses, interval between pulses, and the pulse length into the generator user interface. The generator then delivers a series of short electric pulses between each electrode probe. The energy delivery is hyperechoic and can be monitored under real-time ultrasound.

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Parts Hunter +EasyPay
Recently Certified
Recently Rated
Service Technicians Forum
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对,公司 Copyright ©2001-2019, Inc.